Business & Regulation

A regulatory science push in the UK includes centres for digital transformation, AI and more.

Robert F Kennedy Jr’s recent speech suggests that investigations into childhood vaccines and over-medication could be on the cards.

The Access to Medicine Foundation has developed the 2026 AMR Benchmark to recognize and promote urgency in the ongoing AMR challenge.

Stakeholders explain why the NIH’s move to cap indirect costs associated with research grants could damage medical innovation.

Why you shouldn’t neglect the importance of blending people, culture, and strategy to foster success in a business.

US-based pharmaceutical associations fear the supply chain repercussions of tariffs, and offer advice for a more sustainable alternative.

We speak with Sanofi’s Anju Bhalla about its appeal against NICE’s final draft guidance for Sarclisa.

Senate committee votes in favor of the nomination; full Senate vote will be next.

Being part of the cell and gene therapy field is an incredible privilege, according to Frank Mathias, CEO, Oxford Biomedica.

Here’s a roundup of ten of the most eye-catching deals so far in 2025.